Terms: = Lymphoma AND MYCL, LMYC, 4610, MYCL1, ENSG00000116990 AND Prognosis
2 results:
1. Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers.
Schick M; Habringer S; Nilsson JA; Keller U
Br J Haematol; 2017 Dec; 179(5):724-738. PubMed ID: 29171017
[TBL] [Abstract] [Full Text] [Related]
2. A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers.
Jung M; Russell AJ; Liu B; George J; Liu PY; Liu T; DeFazio A; Bowtell DD; Oberthuer A; London WB; Fletcher JI; Haber M; Norris MD; Henderson MJ
Cancer Res; 2017 Feb; 77(4):971-981. PubMed ID: 27923830
[TBL] [Abstract] [Full Text] [Related]
